RxDoctor Payments Data

Timothy Spurling, MD

Gastroenterology · Florence, SCNPI 1407804909

Payments from drug & device makers

$3,940in general payments, 2019–2025

Across 256 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$323
  • Johnson & Johnson$184
  • Takeda Pharmaceuticals U.S.A., Inc.$173
  • Pfizer$144
  • Janssen Scientific Affairs, LLC$102
  • plus $870 from 26 others

What the payments were for

  • Food & beverage$3,84097%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,940 in reported general payments places this provider in the 55th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$103,245
Medicare patients
508
Services billed
838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab26$332,022
Humira PenAdalimumab13$167,821
RinvoqUpadacitinib17$120,914
Cimzia (2 Pack)Certolizumab Pegol14$107,465
XifaxanRifaximin16$62,154
LinzessLinaclotide19$14,042
Mesalamine39$9,816
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates116$7,375
Ursodiol38$5,865
Dexlansoprazole DrDexlansoprazole19$5,064
Entecavir13$4,104
Pantoprazole Sodium264$3,790
Budesonide DrBudesonide20$2,466
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl126$2,151
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl89$1,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess$2,144$134,95636 claims
UCB, Inc.Cimzia (2 Pack)$87$107,46514 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$323$62,15416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →